2015
Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings
Chahine M, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, Investigators T. Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. Movement Disorders 2015, 31: 86-94. PMID: 26293177, PMCID: PMC4827252, DOI: 10.1002/mds.26373.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnxietyAttentionCocaineCognition DisordersCohort StudiesExecutive FunctionFemaleHumansLanguageMaleMemoryMiddle AgedNeurogenic BowelNeuropsychological TestsOlfaction DisordersParkinson DiseaseProtein BindingRadiopharmaceuticalsSelf ReportSeverity of Illness IndexStatistics, NonparametricSurveys and QuestionnairesTomography, Emission-Computed, Single-PhotonVisual PerceptionConceptsExecutive function/Global cognitionRelative impairmentSpecific cognitive domainsSpeed/attentionGlobal cognitive abilityNeuropsychological test batteryLower global cognitionFunction/Cognitive abilitiesCognitive domainsCognitive profileVisuospatial abilitiesLanguage domainsCognitive testingTest batteryCognitionNormative scoresMemoryLower mean scoresHealthy adultsNon-motor featuresIndividualsStudy findingsNon-motor symptomsCognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors
2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis
Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research 2012, 206: 195-199. PMID: 23159196, PMCID: PMC3600156, DOI: 10.1016/j.psychres.2012.10.013.Peer-Reviewed Original ResearchConceptsClinical high riskCHR individualsComprehensive cognitive test batteryCognitive test batteryCognitive impairmentFuture longitudinal researchCognitive functioningCognitive performanceCognitive testsTest batteryLongitudinal researchCognitionPoor performanceLongitudinal changesPsychosisIndividualsParticipantsImpairmentBaseline participantsFunctioningPerformanceBatteriesResearchProdromeGlycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptomsTraditional neuropsychological correlates and reliability of the Automated Neuropsychological Assessment Metrics-4 battery for Parkinson’s disease
Hawkins KA, Jennings D, Vincent AS, Gilliland K, West A, Marek K. Traditional neuropsychological correlates and reliability of the Automated Neuropsychological Assessment Metrics-4 battery for Parkinson’s disease. Parkinsonism & Related Disorders 2012, 18: 864-870. PMID: 22609082, DOI: 10.1016/j.parkreldis.2012.04.021.Peer-Reviewed Original Research
2010
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. JAMA Psychiatry 2010, 67: 578-588. PMID: 20530007, PMCID: PMC3332118, DOI: 10.1001/archgenpsychiatry.2010.66.Peer-Reviewed Original ResearchConceptsFamily historyCHR individualsNeuropsychological functioningCHR syndromeNorth American Prodrome Longitudinal StudyClinical high-risk individualsHigh-risk groupFirst-episode schizophreniaBaseline neuropsychological evaluationHigh-risk individualsSecond-degree relativesHigh-risk statusLongitudinal studyGlobal neuropsychological functioningWorse verbal memoryPrediction of psychosisCHR assessmentSyndrome criteriaProspective evaluationClinical criteriaModerate severityNeurocognitive composite scorePsychosis onsetNormal controlsSubsequent psychosis
2009
Endophenotypes in schizophrenia: A selective review
Allen AJ, Griss ME, Folley BS, Hawkins KA, Pearlson GD. Endophenotypes in schizophrenia: A selective review. Schizophrenia Research 2009, 109: 24-37. PMID: 19223268, PMCID: PMC2665704, DOI: 10.1016/j.schres.2009.01.016.Peer-Reviewed Original Research
2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessmentEveryday Decision-Making Ability in Older Persons With Cognitive Impairment
Lai JM, Gill TM, Cooney LM, Bradley EH, Hawkins KA, Karlawish JH. Everyday Decision-Making Ability in Older Persons With Cognitive Impairment. American Journal Of Geriatric Psychiatry 2008, 16: 693-696. PMID: 18669948, PMCID: PMC2730037, DOI: 10.1097/jgp.0b013e31816c7b54.Peer-Reviewed Original ResearchConceptsDecision-making abilityDecision-making capacityCognitive impairmentMacArthur Competency Assessment ToolExecutive functionMeasure of understandingOverall cognitionAssessment of capacityValid measureAlpha coefficientMedical treatment decisionsCronbach's alpha coefficientGood reliabilityImpairmentMeasuresACEDModerate correlationOlder personsCognitionAssessment toolPersonsAbilityReasoningCaregiversEveryday
2002
Factors Affecting Cognitive Functioning in a Sample of Human Immunodeficiency Virus-Positive Injection Drug Users
Margolin A, Avants SK, Warburton LA, Hawkins KA. Factors Affecting Cognitive Functioning in a Sample of Human Immunodeficiency Virus-Positive Injection Drug Users. AIDS Patient Care And STDs 2002, 16: 255-267. PMID: 12133261, DOI: 10.1089/10872910260066697.Peer-Reviewed Original ResearchConceptsCognitive functioningTest performanceNeuropsychological test performanceSelf-report measuresVisual-motor coordinationNP test performanceInjection drug usersEvidence of impairmentDrug useCognitive flexibilityNP test batteryVerbal informationNation's inner citiesTest batteryEducational attainmentDrug-abusing individualsDrug usersSubstance abuseCognitive impairmentIndependent contributionTreatment interventionsViral loadLittle researchPsychiatric problemsSuccessful engagementRelationship between Alcohol Consumption and Folstein Mini-Mental Status Examination Scores among Older Cognitively Impaired Adults
Reid MC, Maciejewski PK, Hawkins KA, Bogardus ST. Relationship between Alcohol Consumption and Folstein Mini-Mental Status Examination Scores among Older Cognitively Impaired Adults. Journal Of Geriatric Psychiatry And Neurology 2002, 15: 31-37. PMID: 11936241, DOI: 10.1177/089198870201500107.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlcohol DrinkingCognition DisordersFemaleHumansMaleMental Status ScheduleConceptsAlcohol abuse/dependenceAbuse/dependenceCognitive screenMMSE subscoresLower total MMSE scoresMMSE scoresDistinctive cognitive profileCognitive impairmentBrief cognitive screenAdverse cognitive outcomesTotal MMSE scoreAlcohol historyCognitive measuresCognitive domainsCognitive profileAlcohol consumptionMini - mental status examination testMini-Mental Status Examination scoreCognitive outcomesAlcohol abuse/dependence disordersImpaired adultsCurrent alcohol intakeMiddle-aged adultsSignificant alcohol historyComprehensive geriatric assessment
2000
Verbal Fluency Deficits Co‐Occur with Memory Deficits in Geriatric Patients at Risk for Dementia: Implications for the Concept of Mild Cognitive Impairment
Cottingham ME, Hawkins KA. Verbal Fluency Deficits Co‐Occur with Memory Deficits in Geriatric Patients at Risk for Dementia: Implications for the Concept of Mild Cognitive Impairment. Behavioural Neurology 2000, 22: 73-79. PMID: 20595739, PMCID: PMC5434323, DOI: 10.3233/ben-2009-0246.Peer-Reviewed Original ResearchConceptsMemory deficitsMemory groupFluency performanceMild cognitive impairmentLower memory performanceCognitive impairmentPhonemic fluency taskMemory test scoresAmnestic mild cognitive impairmentAlzheimer's disease (AD) displayMemory patientsMemory performanceFluency taskMemory scoresSemantic fluencyCognitive complaintsFluency testMemory abilityFluency scoresDisease displayTest scoresDeficitsClinical presentationGeriatric patientsPatient group
1999
California Verbal Learning Test practice effects in a schizophrenia sample
Hawkins K, Wexler B. California Verbal Learning Test practice effects in a schizophrenia sample. Schizophrenia Research 1999, 39: 73-78. PMID: 10480669, DOI: 10.1016/s0920-9964(99)00015-8.Peer-Reviewed Original ResearchConceptsPractice effectsCalifornia Verbal Learning TestVerbal Learning TestTest practice effectsLearning TestWeek 10Sample of personsNew learningSchizophrenia sampleLater performancePrior exposureNon-pharmacological interventionsSerial performanceSample of patientsClinical circumstancesWeek 14Psychiatric statusLearningSchizophreniaCVLTExact natureMemoryConsiderable retentionLarge effectExposureWill the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia?
HAWKINS KA, MOHAMED S, WOODS SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychological Medicine 1999, 29: 1-8. PMID: 10077288, DOI: 10.1017/s0033291798006990.Peer-Reviewed Original ResearchConceptsNovel antipsychoticsNegative symptomsNeuropsychological deficitsSevere psychiatric illnessNew antipsychotic medicationsTreatment of schizophreniaCognitive outcome dataAntipsychotic medicationConventional neurolepticsNeurodevelopmental aberrationsClinical effectivenessNew antipsychoticsUnderlying pathophysiologyClinical reasonsPsychiatric illnessImproved complianceOutcome dataFunctional capacityNeurological effectsAntipsychoticsAuditory hallucinationsNeurocognitive changesMedicationsNeural tissueSymptoms